I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...

Effect of intravenous IgG therapy on natural killer cell function related to Fc gamma receptor gene expression ... The architecture of the IgG anti-carbohydrate repertoire in primary antibody ...

Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024: Watertown, Massachusetts Tuesday, November 12, 2024, 13:00 ...

(NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with ...

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

The case law distinguishes between so-called “unpredictable arts” (e.g., the biological, chemical, and pharmaceutical arts) ...

Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses. In a new study, ...